Bank of America Corp DE Trims Stock Holdings in National Research Co. (NASDAQ:NRC)

Bank of America Corp DE reduced its stake in National Research Co. (NASDAQ:NRC) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,657 shares of the company’s stock after selling 7,157 shares during the quarter. Bank of America Corp DE owned about 0.48% of National Research worth $1,970,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Geode Capital Management LLC lifted its position in National Research by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 435,707 shares of the company’s stock worth $7,687,000 after buying an additional 14,974 shares during the period. Renaissance Technologies LLC lifted its position in National Research by 6.6% during the fourth quarter. Renaissance Technologies LLC now owns 404,886 shares of the company’s stock worth $7,142,000 after buying an additional 25,002 shares during the period. Northern Trust Corp lifted its position in National Research by 2.7% during the fourth quarter. Northern Trust Corp now owns 293,755 shares of the company’s stock worth $5,182,000 after buying an additional 7,853 shares during the period. Bank of New York Mellon Corp lifted its position in National Research by 88.5% during the fourth quarter. Bank of New York Mellon Corp now owns 217,212 shares of the company’s stock worth $3,832,000 after buying an additional 101,957 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in National Research by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 124,711 shares of the company’s stock worth $2,200,000 after buying an additional 970 shares during the period. 47.26% of the stock is currently owned by hedge funds and other institutional investors.

National Research Stock Performance

NASDAQ NRC opened at $14.12 on Wednesday. The company has a market capitalization of $321.72 million, a PE ratio of 13.45 and a beta of 0.34. The company has a current ratio of 0.47, a quick ratio of 0.47 and a debt-to-equity ratio of 1.30. The business’s 50-day moving average price is $12.42 and its 200 day moving average price is $15.43. National Research Co. has a twelve month low of $9.76 and a twelve month high of $28.26.

National Research (NASDAQ:NRC) last announced its quarterly earnings results on Monday, April 28th. The company reported $0.25 EPS for the quarter. The company had revenue of $33.55 million during the quarter. National Research had a return on equity of 66.52% and a net margin of 17.32%.

National Research Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 3.40%. National Research’s dividend payout ratio (DPR) is currently 46.60%.

Insider Activity

In related news, major shareholder Patrick E. Beans bought 2,500 shares of the stock in a transaction dated Monday, May 12th. The stock was acquired at an average price of $13.59 per share, for a total transaction of $33,975.00. Following the completion of the purchase, the insider now owns 35,003 shares in the company, valued at $475,690.77. This represents a 7.69% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.10% of the company’s stock.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.